CapsoVision (CV)
Market Price (11/6/2026): $6.2 | Market Cap: $329.9 MilSector: Health Care | Industry: Life Sciences Tools & Services
CapsoVision (CV)
Market Price (11/6/2026): $6.2Market Cap: $329.9 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -166% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -217% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 10% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -200%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -201% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 21.23 Key risksCV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -166% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -30 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -217% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 10% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -200%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -201% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 21.23 |
| Key risksCV key risks include [1] significant financial strain and a heightened bankruptcy risk, Show more. |
Qualitative Assessment
AI Analysis | Feedback
CapsoVision (CV) stock has lost about 5% since 7/31/2026 because of the following key factors:
1. Fiscal Q2 2026 Earnings Miss and Increased Net Loss. CapsoVision reported a net loss of $7.48 million for fiscal Q2 2026, which ended on June 30, 2026. This represented a 61.7% increase in losses compared to fiscal Q2 2025, with a diluted loss per share of $(0.15) that missed analyst estimates by $0.04. This negative financial performance led to a 7.7% after-hours decline in the stock price following the earnings announcement on August 13, 2026.
2. Pressure on Gross Margins and Rising Operating Expenses. The company experienced a decline in its gross margin for fiscal Q2 2026, falling to 51% from 55% in the prior year's comparable quarter. This reduction was primarily attributed to pricing pressure in a highly competitive market and increased expenses stemming from U.S. government trade policies and tariffs. Simultaneously, operating expenses rose significantly by $3.0 million, or 46%, reaching $9.5 million. This increase was driven by investments in the colon pivotal study, other clinical trials, and costs associated with operating as a public company.
Show more
CapsoVision (CV) stock has lost about 5% since 7/31/2026 because of the following key factors:
1. Fiscal Q2 2026 Earnings Miss and Increased Net Loss. CapsoVision reported a net loss of $7.48 million for fiscal Q2 2026, which ended on June 30, 2026. This represented a 61.7% increase in losses compared to fiscal Q2 2025, with a diluted loss per share of $(0.15) that missed analyst estimates by $0.04. This negative financial performance led to a 7.7% after-hours decline in the stock price following the earnings announcement on August 13, 2026.
2. Pressure on Gross Margins and Rising Operating Expenses. The company experienced a decline in its gross margin for fiscal Q2 2026, falling to 51% from 55% in the prior year's comparable quarter. This reduction was primarily attributed to pricing pressure in a highly competitive market and increased expenses stemming from U.S. government trade policies and tariffs. Simultaneously, operating expenses rose significantly by $3.0 million, or 46%, reaching $9.5 million. This increase was driven by investments in the colon pivotal study, other clinical trials, and costs associated with operating as a public company.
3. Equity Offerings to Address Capital Needs. During the period, CapsoVision initiated an At-The-Market (ATM) equity program for up to $100 million in August 2026 and subsequently announced an $18 million direct stock offering in September 2026. While these offerings are intended to secure capital for ongoing clinical trials and product development, such share issuances can signal a need for funding and potentially lead to the dilution of existing shares, which can exert downward pressure on the stock's valuation.
Show less
Stock Movement Drivers
Fundamental Drivers
The -5.8% change in CV stock from 7/31/2026 to 11/5/2026 was primarily driven by a -5.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.58 | 6.20 | -5.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 14 | 2.4% |
| P/S Multiple | 23.0 | 22.3 | -3.2% |
| Shares Outstanding (Mil) | 47 | 50 | -5.0% |
| Cumulative Contribution | -5.8% |
Market Drivers
7/31/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| CV | -5.8% | |
| Market (SPY) | -1.9% | 35.3% |
| Sector (XLV) | 13.8% | 2.3% |
Fundamental Drivers
The -12.4% change in CV stock from 4/30/2026 to 11/5/2026 was primarily driven by a -9.0% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.08 | 6.20 | -12.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 14 | 2.5% |
| P/S Multiple | 24.5 | 22.3 | -9.0% |
| Shares Outstanding (Mil) | 47 | 50 | -6.2% |
| Cumulative Contribution | -12.4% |
Market Drivers
4/30/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| CV | -12.4% | |
| Market (SPY) | 2.3% | 22.2% |
| Sector (XLV) | 27.2% | 6.3% |
Fundamental Drivers
The 27.0% change in CV stock from 10/31/2025 to 11/5/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.88 | 6.20 | 27.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 14 | 0.0% |
| P/S Multiple | � | 22.3 | 0.0% |
| Shares Outstanding (Mil) | 41 | 50 | -18.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 11/5/2026| Return | Correlation | |
|---|---|---|
| CV | 27.0% | |
| Market (SPY) | 8.4% | 13.1% |
| Sector (XLV) | 29.8% | 15.2% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/5/2026| Return | Correlation | |
|---|---|---|
| CV | -82.4% | |
| Market (SPY) | 81.3% | 11.7% |
| Sector (XLV) | 55.5% | 10.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CV Return | 0% | 0% | 0% | 0% | -70% | -42% | -82% |
| Peers Return | 4% | -15% | -8% | -24% | 55% | -9% | -12% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| CV Win Rate | 0% | 0% | 0% | 0% | 33% | 45% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 56% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| CV Max Drawdown | 0% | 0% | 0% | 0% | -90% | -57% | |
| Peers Max Drawdown | -33% | -44% | -52% | -42% | -36% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, COCH, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/5/2026 (YTD)
How Low Can It Go
| Event | CV | S&P 500 |
|---|---|---|
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -12.6% | -15.4% |
| % Gain to Breakeven | 14.4% | 18.2% |
| Time to Breakeven | 190 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -47.4% | -53.4% |
| % Gain to Breakeven | 90.2% | 114.4% |
| Time to Breakeven | 922 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -18.7% | -8.6% |
| % Gain to Breakeven | 23.0% | 9.5% |
| Time to Breakeven | 1375 days | 47 days |
In The Past
CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CV | S&P 500 |
|---|---|---|
| 2008-2009 Global Financial Crisis | ||
| % Loss | -47.4% | -53.4% |
| % Gain to Breakeven | 90.2% | 114.4% |
| Time to Breakeven | 922 days | 1085 days |
In The Past
CapsoVision's stock fell -0.7% during the 2011 US Debt Ceiling Crisis & European Contagion. Such a loss loss requires a 0.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CapsoVision (CV)
CapsoVision (CV) is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) solutions for diagnosing abnormalities of the gastrointestinal (GI) tract. Its flagship product is the CapsoCam Plus, a single-use, wire-free capsule endoscopy system designed for panoramic visualization of the small-bowel mucosa. This system, which includes the physical capsule and proprietary CapsoCloud/CapsoView software, allows healthcare providers to identify conditions such as obscure GI bleeding and Crohn's disease without the need for patient-worn data recorders, offering clinicians a flexible, zero-capex workflow. CapsoVision primarily serves gastroenterologists in clinics and hospitals, selling directly in the U.S. and both directly and through qualified distributors in international markets like France, Germany, and Canada.
The company has demonstrated consistent growth, with revenues increasing from $9.8 million in 2023 to $11.8 million in 2024, representing 21% year-over-year growth, primarily driven by increasing CapsoCam Plus unit sales. CapsoVision is expanding its technology with the upcoming integration of AI-assisted reading for CapsoCam Plus, targeting FDA clearance and commercialization by late 2025 to reduce review time for clinicians. Looking ahead, the company is developing CapsoCam Colon, a pipeline product that incorporates AI for automatic polyp detection and a 3D sensor for size measurement, with revenues for its second generation targeted for the U.S. in late 2026 and the EU in early 2027. Longer-term, CapsoVision plans to adapt its panoramic imaging for new GI indications such as esophageal varices and pancreatic cancer, with feasibility studies beginning in 2025 and 2026.
AI Analysis | Feedback
- It's like a high-tech, disposable GoPro for your digestive system, with AI to help doctors quickly find problems.
- Think of it as the 'Cologuard of visual GI diagnostics,' offering a less invasive way for doctors to inspect your insides with a smart camera pill, instead of traditional procedures.
AI Analysis | Feedback
- CapsoCam Plus System: A capsule endoscopy solution, including a single-use capsule and viewing software (CapsoCloud/CapsoView), designed for panoramic visualization and diagnosis of small-bowel abnormalities.
- CapsoCam Plus with AI Assisted Reading: An upcoming update to the CapsoCam Plus system that will incorporate AI to detect and highlight suspected abnormalities, aiming to reduce clinician review time.
- CapsoCam Colon (Pipeline): A developing capsule endoscope product designed to automatically detect polyps and measure their size in the colon using integrated AI and a 3D sensor.
- Future CapsoCam Applications (Pipeline): Longer-term adaptations of the CapsoCam platform being explored for new GI medical indications such as esophageal conditions and pancreatic cancer.
AI Analysis | Feedback
CapsoVision (CV) sells primarily to other companies and medical institutions. Based on the provided information, the company's major customers fall into the following categories:
- Hospitals
- Clinics (specifically those where gastroenterologists practice)
- Qualified exclusive distributors (for international sales)
The provided text does not name specific customer companies or their symbols.
AI Analysis | Feedback
AI Analysis | Feedback
Kang-Huai (Johnny) Wang, President, Chief Executive Officer and Director
Mr. Wang is a co-founder of CapsoVision, and has served as President and Chief Executive Officer since November 2024. He previously served as CapsoVision's President and Chief Technology Officer from October 2006 to October 2024. Prior to joining CapsoVision, he was Vice President of Engineering for ESS Technology and also served as Chief Executive Officer and co-founder of Divio, Inc., a video processing chip design company. Mr. Wang was also a Design Manager for C-Cube Microsystem and held various engineering roles in the semiconductor industry.
David Michael Garcia, Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
Mr. Garcia serves as Senior Vice President, Finance at CapsoVision, overseeing the company's financial strategy, planning, and operations, and brings over 20 years of financial leadership experience. Before joining CapsoVision, he was Vice President of Financial Planning and Analysis at Matterport, Inc. from 2020 to 2025, where he played a key role in the company's initial public offering and its subsequent acquisition. His prior experience includes senior finance roles at View, Inc., IntelePeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte.
Douglas Atkinson, Senior Vice President of Global Sales
Mr. Atkinson joined CapsoVision as Head of Global Sales in October 2016. Before CapsoVision, he was Director of Sales for MedTech Micro-Fixation from May 2015 to October 2016. He also served as Regional Sales Director at Medtronic PLC from January 2005 to April 2015, and as Regional Director of Sales and National Accounts at Stryker Corporation from May 1995 to December 2004, where he was recognized for multiple sales leadership and revenue growth awards.
AI Analysis | Feedback
Key Risks to CapsoVision (CV)
- Going Concern and Liquidity Risk: CapsoVision has a history of operating losses, an accumulated deficit, and a stated substantial doubt about its ability to continue as a going concern, which could adversely impact its ability to fund growth strategies and meet cash and liquidity needs.
- Regulatory Clearance Delays or Failure: The company's ability to commercialize its updated CapsoCam Plus with AI-assisted reading technology and its new pipeline product, CapsoCam Colon, is dependent on receiving timely FDA 510(k) clearances and EU CE Marks, which may be delayed or not obtained at all, impacting future revenue generation.
- Dependence on a Single Product and Market Competition: All current revenues are derived from the CapsoCam Plus for small bowel visualization, making the company highly dependent on the continued success and growth of this single product. Its ability to grow is also subject to intense competition from existing FDA-cleared products and established market players.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
CapsoVision (CV) anticipates several key drivers for future revenue growth over the next 2-3 years:
- Expanded Sales of CapsoCam Plus System: The company plans to further grow its existing sales and marketing team to increase sales of its CapsoCam Plus small-bowel capsule system, building on its consistent revenue growth and high customer retention rate of approximately 90% in 2024. This includes strengthening its market presence, as evidenced by establishing a direct sales team in Germany in 2023.
- Commercialization of AI-Assisted CapsoCam Plus: CapsoVision is updating its CapsoCam Plus with self-developed AI-assisted reading technology. The company targets FDA 510(k) and EU submissions in the second half of 2025, with clearance of the updated capsule and subsequent commercialization by the end of 2025. This enhancement is expected to make capsule endoscopy more financially attractive to practices by reducing video review time.
- Launch of CapsoCam Colon System: To expand beyond small-bowel sales, CapsoVision is developing CapsoCam Colon, a new capsule endoscope for colon visualization, incorporating AI for polyp detection and a 3D sensor for polyp-size measurement. The company targets U.S. revenues for its second-generation CapsoCam Colon system beginning in the second half of 2026, following FDA 510(k) clearance, and EU revenues in early 2027, after receiving a CE Mark.
AI Analysis | Feedback
Peer Outperformance in Life Sciences Tools & Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.6% | 56.6% | 93.6% | CAH 498% · MCK 396% · COR 181% |
| Health Care Services | 20 | 33.8% | 28.8% | 6.1% | HIMS 189% · RDNT 125% · DGX 100% |
| Health Care Facilities | 25 | 13.9% | 27.4% | -1.4% | THC 280% · NHC 210% · EHC 186% |
| Managed Health Care | 8 | 47.9% | 1.6% | -2.2% | OSCR 95% · HQY 52% · ELV 10% |
| Health Care Equipment | 50 | 11.0% | 17.8% | -17.6% | UFPT 355% · GKOS 286% · PLSE 127% |
| Pharmaceuticals | 61 | -12.9% | 10.6% | -37.3% | LQDA 977% · XERS 571% · KNSA 500% |
| Health Care Supplies | 11 | 23.9% | 17.0% | -40.1% | LNTH 248% · HAE 66% · MMSI 29% |
| Life Sciences Tools & Services ← | 108 | -8.1% | -18.9% | -74.5% | AXGN 255% · NTRA 214% · MEDP 181% |
| Biotechnology | 364 | -25.8% | -36.1% | -82.0% | ELVN 1073% · TRVI 995% · DNTH 956% |
| Health Care Technology | 21 | -21.4% | -50.4% | -82.8% | VEEV -3% · DOCS -51% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.36 |
| Mkt Cap | 0.8 |
| Rev LTM | 227 |
| Op Inc LTM | -24 |
| FCF LTM | -10 |
| FCF 3Y Avg | -13 |
| CFO LTM | 3 |
| CFO 3Y Avg | 2 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.1% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 13.5% |
| Op Inc Chg 3Y Avg | 21.7% |
| Op Mgn LTM | -3.0% |
| Op Mgn 3Y Avg | -8.3% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 1.5% |
| CFO/Rev 3Y Avg | -0.6% |
| FCF/Rev LTM | -1.2% |
| FCF/Rev 3Y Avg | -7.0% |
Price Behavior
| Market Price | $6.20 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -57.0% | |
| 50 Days | 200 Days | |
| DMA Price | $6.48 | $6.36 |
| DMA Trend | up | down |
| Distance from DMA | -4.4% | -2.5% |
| 3M | 1YR | |
| Volatility | 53.7% | 98.6% |
| Downside Capture | 175.77 | 96.95 |
| Upside Capture | 163.92 | 129.83 |
| Correlation (S&P 500) | 17.1% | 10.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.39 | 0.24 | 0.91 | 0.70 | 0.79 | 0.15 |
| Up Beta | 1.53 | -2.26 | -0.57 | -1.19 | -0.35 | 0.10 |
| Down Beta | 1.45 | 1.06 | 0.21 | 1.45 | 0.74 | 0.27 |
| Up Capture | 38% | 90% | 156% | 78% | 151% | -5% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 11 | 25 | 32 | 62 | 122 | 167 |
| Down Capture | -50% | -45% | 133% | 116% | 99% | 35% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 10 | 17 | 31 | 63 | 125 | 164 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CV | |
|---|---|---|---|---|
| CV | 35.2% | 98.6% | 0.73 | - |
| Sector ETF (XLV) | 29.2% | 16.9% | 1.33 | 15.3% |
| Equity (SPY) | 9.5% | 13.6% | 0.41 | 12.8% |
| Gold (GLD) | 3.6% | 28.7% | 0.11 | 1.3% |
| Commodities (DBC) | 37.7% | 21.2% | 1.40 | -5.6% |
| Real Estate (VNQ) | 12.0% | 14.2% | 0.55 | 6.0% |
| Bitcoin (BTCUSD) | -20.8% | 43.3% | -0.42 | 0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CV | |
|---|---|---|---|---|
| CV | 8.2% | 90.5% | 0.71 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 11.8% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 12.9% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 0.9% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -2.3% |
| Real Estate (VNQ) | 1.2% | 18.9% | -0.05 | 6.0% |
| Bitcoin (BTCUSD) | 5.9% | 51.5% | 0.29 | 1.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CV | |
|---|---|---|---|---|
| CV | 4.0% | 90.5% | 0.71 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.60 | 11.8% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 12.9% |
| Gold (GLD) | 12.0% | 16.5% | 0.59 | 0.9% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | -2.3% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 6.0% |
| Bitcoin (BTCUSD) | 61.3% | 66.2% | 1.01 | 1.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/28/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/13/2026 | -4.9% | -13.0% | -4.1% |
| 5/14/2026 | -11.6% | -7.3% | -1.0% |
| 3/26/2026 | -0.3% | -1.2% | -15.4% |
| 11/13/2025 | -9.7% | -6.0% | 111.6% |
| 8/14/2025 | -4.2% | -1.0% | 7.7% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 2 |
| # Negative | 5 | 5 | 3 |
| Median Positive | 59.7% | ||
| Median Negative | -4.9% | -6.0% | -4.1% |
| Max Positive | 111.6% | ||
| Max Negative | -11.6% | -13.0% | -15.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/13/2026 | -4.9% | -13.0% | -4.1% |
| 5/14/2026 | -11.6% | -7.3% | -1.0% |
| 3/26/2026 | -0.3% | -1.2% | -15.4% |
| 11/13/2025 | -9.7% | -6.0% | 111.6% |
| 8/14/2025 | -4.2% | -1.0% | 7.7% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 2 |
| # Negative | 5 | 5 | 3 |
| Median Positive | 59.7% | ||
| Median Negative | -4.9% | -6.0% | -4.1% |
| Max Positive | 111.6% | ||
| Max Negative | -11.6% | -13.0% | -15.4% |
Insider Activity
Updated 9/23/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Harari, Eliyahou ET AL | trust. | Buy | 9232026 | 5.69 | 1,757,469 | 9,999,999 | 7,946,051 | Form | |
| 2 | Shen, Ching Hang | Star One Global Capital Limited | Buy | 9182026 | 5.69 | 878,734 | 4,999,996 | 16,652,667 | Form | |
| 3 | Harari, Eliyahou ET AL | trust. | Buy | 7202026 | 6.73 | 61,068 | 410,988 | 22,499,191 | Form | |
| 4 | Harari, Eliyahou ET AL | trust. | Buy | 7102026 | 6.09 | 81,300 | 495,117 | 19,987,691 | Form | |
| 5 | Harari, Eliyahou ET AL | trust. | Buy | 7022026 | 7.35 | 13,850 | 101,811 | 23,528,721 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Harari, Eliyahou ET AL | trust. | Buy | 9232026 | 5.69 | 1,757,469 | 9,999,999 | 7,946,051 | Form | |
| 2 | Shen, Ching Hang | Star One Global Capital Limited | Buy | 9182026 | 5.69 | 878,734 | 4,999,996 | 16,652,667 | Form | |
| 3 | Harari, Eliyahou ET AL | trust. | Buy | 7202026 | 6.73 | 61,068 | 410,988 | 22,499,191 | Form | |
| 4 | Harari, Eliyahou ET AL | trust. | Buy | 7102026 | 6.09 | 81,300 | 495,117 | 19,987,691 | Form | |
| 5 | Harari, Eliyahou ET AL | trust. | Buy | 7022026 | 7.35 | 13,850 | 101,811 | 23,528,721 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.